RESUMO
Objective: To evaluate the efficacy and adverse effects of hypoglossal nerve stimulation in adolescents with down syndrome and obstructive sleep apnea. Methods: A systematic search was conducted using PubMed, Web of Science, Embase, and Scopus databases. The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search strategy used a combination of Medical Subject Headings and free words with "OR" and "AND." Articles were screened to extract data reporting apnea-hypopnea index, quality of life, voltage, follow-up duration, and complications. All included participants were adolescents with down syndrome and obstructive sleep apnea. Results: A total of 92 articles were identified, of which 9 articles met the inclusion criteria. A total of 106 patients were included. All the studies showed that patients receiving hypoglossal nerve stimulation experienced a significant decrease in apnea-hypopnea index (at least 50%). The pooled AHI was significantly lower in patients following treatment (mean AHI reduction 17.43 events/h, 95% confidence interval 13.98-20.88 events/h, P < 0.001) after 2 case reports were excluded. The pooled OSA-18 were significantly decreased in 88 patients after treatment (mean OSA-18 reduction 1.67, 95% confidence interval 1.27-2.08, P < 0.001) after excluding 5 studies. Four investigations examined the necessity to optimize stimulation voltage for arousal during treatment. The most common complication was pain or discomfort in the tongue or mouth. Most studies had relatively short patient follow-up periods, with the most extended follow-up being 44-58 months. Conclusion: Hypoglossal nerve stimulation significantly reduces apnea-hypopnea index and improves the quality of life; and thus, could be a potential alternative therapy for obstructive sleep apnea in adolescents with down syndrome. The adolescent's age, potential complications, adverse events, long-term efficacy, and comfort, needs to be considered while performing hypoglossal nerve stimulation.
RESUMO
BACKGROUND: Patients with Parkinson's disease (PD) are at a lower risk of suffering cardiovascular events, but the underlying factors for this decreased risk remain unclear. Serum triglycerides (TG) and total cholesterol (TC), and their expression relative to high-density lipoprotein cholesterol (TG/HDL-C and TC/HDL-C), are independent predictors of cardiovascular events. This study aimed to determine if PD patients have decreased lipid levels and lipid ratios, which may underlie the decreased risk of coronary heart disease (CHD). METHODS: This retrospective study included 92 PD patients (PD group), 450 control subjects with no CHD (OD group), and 450 CHD patients (CHD group). We analyzed serum lipid levels and lipid ratios in each group. RESULTS: There were significant differences in TC (F = 10.459, p < 0.0001), TG (F = 46.856, p < 0.0001), low density lipoprotein cholesterol (LDL-C) (F = 6.910, p = 0.001), high density lipoprotein cholesterol HDL-C (F = 30.694, p < 0.0001), TC/HDL-C (F = 32.675, p < 0.0001), and TG/HDL-C (F = 45.554, p < 0.0001) between all three groups; TC/LDL-C (F = 2.518, p = 0.081) was not significantly different between groups. Compared to the CHD group, PD patients had lower TC (p < 0.0001), TG (p < 0.0001), LDL-C (p = 0.001), TG/HDL-C (p < 0.0001), and TC/HDL-C (p < 0.0001); TC/LDL-C (p = 0.563) and HDL-C (p = 0.196) were not significantly different. TC and LDL-C levels were positively correlated within individual groups (all p < 0.0001). In addition, TG and HDL-C were negatively correlated in the OD and CHD groups (p < 0.0001); no significant negative association was observed in the PD group (p = 0.077). TG/HDL and LDL-C levels were inversely correlated in the CHD group (p < 0.0001) and weakly positively correlated in the PD (p = 0.159) and OD (p = 0.199) groups. CONCLUSIONS: TC/HDL and TG/HDL ratios were significantly lower in PD patients compared to CHD patients, suggesting there is a strong correlation between lipid ratios and incidence of CHD in PD patients.
